GO
Loading...

Gilead Sciences Inc

More

  • Early Glance: Biotechnology companies Thursday, 9 Oct 2014 | 11:31 AM ET

    Amgen Inc. fell$. 91 or. 6 percent, to $139.16. Biogen Idec fell $3.36 or 1.0 percent, to $321.23. Celgene Corp. fell $1.08 or 1.1 percent, to $93.81.

  • NEA, known for backing companies such as Workday Inc, Salesforce.com Inc and Gilt Groupe, is one of the world's top venture firms, with its latest fund totalling $2.6 billion. Health science is one area where women venture capitalists appear to be making serious gains, with some of the most accomplished health investors, including Beth Seidenberg of Kleiner...

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...

  • Lightning Round: Trinity, Berkshire Hathaway & more Thursday, 2 Oct 2014 | 6:50 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer: Stocks reflect America’s innovative spirit Wednesday, 24 Sep 2014 | 6:21 PM ET

    If you’re looking for stock ideas, Cramer says thanks to good ol’ American ingenuity, this sector is bursting with them.

  • Indexes added to gains and hit session highs after Chicago Federal Reserve Bank President Charles Evans said the central bank should be "exceptionally patient" in removing monetary policy accommodation at a Peterson Institute conference on labor market slack.

  • US STOCKS-Biotechs climb after two-day drop Wednesday, 24 Sep 2014 | 1:48 PM ET

    NEW YORK, Sept 24- Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.

  • Gilead's HIV drug shows potential in two mid-stage studies Wednesday, 24 Sep 2014 | 10:20 AM ET

    Sept 24- Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies. The company's shares rose 1.3 percent to $106.77 in early trading on the Nasdaq on Wednesday.

  • Midday movers: DuPont, Kellogg, Lennar, Nike & more Wednesday, 17 Sep 2014 | 12:53 PM ET

    Some of Wednesday's midday movers:

  • Study shows downward trend in Sovaldi utilization Wednesday, 17 Sep 2014 | 8:38 AM ET

    Sept 17- Over the last several months there has been a' plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000- a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December.

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • GILEAD'S EXPERIMENTAL CANCER DRUG FAILS IN MID-STAGE STUDY@. Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve the length of time that patients with a type of pancreatic cancer lived without the disease worsening.

  • Cramer: Tech investors facing Alibaba headache Monday, 15 Sep 2014 | 6:11 PM ET
    Jim Cramer speaks ahead of the Alibaba IPO on Mad Money.

    As the Alibaba IPO nears, Cramer expects a slew of stocks to selloff. He's naming names.

  • Midday movers: Apple, Netflix, RadioShack & more Monday, 15 Sep 2014 | 1:40 PM ET

    Some of Monday's midday movers:

  • NEW YORK, Sept 15- Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis C drug.

  • *Gilead plans to sell Sovaldi in India for $300 a month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the $1,000- a-pill medicine in 91 developing nations.

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • LOS ANGELES, Sept 12- The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

  • NEW YORK, Sept 11- U.S. stocks were down slightly in late afternoon trading on Thursday following a decline in biotechnology shares, but gains in financials helped to limit the day's losses. Shares of JPMorgan Chase were up 0.8 percent, while shares of Bank of America were up 1.1 percent, the two biggest positives on the S&P 500..

  • Like Apple, these firms satisfy unmet need: Cramer Wednesday, 10 Sep 2014 | 6:09 PM ET

    Sometimes when you buy a gadget, you didn’t know how much you needed it, until after you started using it.